Last reviewed · How we verify
Drug: cimetidine
Cimetidine blocks histamine H2 receptors on gastric parietal cells to reduce stomach acid production.
Cimetidine blocks histamine H2 receptors on gastric parietal cells to reduce stomach acid production. Used for Duodenal ulcer, Gastric ulcer, Gastroesophageal reflux disease (GERD).
At a glance
| Generic name | Drug: cimetidine |
|---|---|
| Also known as | Tagamet |
| Sponsor | University of Maryland, Baltimore |
| Drug class | H2 receptor antagonist |
| Target | Histamine H2 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Cimetidine is a competitive antagonist of histamine H2 receptors, which are responsible for stimulating gastric acid secretion. By blocking these receptors, it decreases both basal and stimulated acid production in the stomach. This mechanism makes it effective for treating acid-related gastrointestinal disorders.
Approved indications
- Duodenal ulcer
- Gastric ulcer
- Gastroesophageal reflux disease (GERD)
- Zollinger-Ellison syndrome
- Peptic ulcer disease
Common side effects
- Headache
- Diarrhea
- Dizziness
- Gynecomastia
- Elevated serum creatinine
Key clinical trials
- Persona Cohort Nordic Multicenter Study
- Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel (PHASE2, PHASE3)
- Zimmer ActivBraid Rotator Cuff Repair (RCR) Study
- Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters (EARLY_PHASE1)
- New Approach of Loco Regional Analgesia in Kidney Transplant (NA)
- Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities (PHASE4)
- Drug Excretion in Breast Milk (PHASE4)
- Intramedullary Nail Versus Hip Arthroplasty in Unstable Trochanteric Hip Fractures (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: cimetidine CI brief — competitive landscape report
- Drug: cimetidine updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI